Stock Doctor uses its defined “9 Golden Rules if Investing” methodology which has a demonstrated track record of outperformance over the long term. Its quantitative process has undergone significant back testing which has been further enhanced over the research and investment product’s nearly 30-year history. Stock Doctor also includes a qualitative overlay via its team of analysts who conduct a bottom-up fundamental review before a company is eligible to receive ‘Star Stock’ status.
Daniel Ortisi of Stock Doctor gives us a detailed pre-market commentary on the results of popular small cap RPMGlobal Holdings Ltd (ASX: RUL). Is RUL share price a buy today?
Much has been said about the rapid rise and fall of lithium. It was the hottest sector on the Aussie market from 2020 to the peak in November 2022, driven by an incredible 600% increase in lithium prices.
Daniel Ortisi of Stock Doctor shares a glimpse into the operations, drivers and potential risks of XRF Scientific Limited (ASX: XRF). Is XRF share price a buy today?
Drinks and hotels business Endeavour Group Ltd (ASX: EDV) recently held its Investor Day. The Analyst Team at Stock Doctor has provided an updated review of Endeavour Group, including our thoughts as to why the stock may be an undervalued opportunity for long-term investors.
There are a lot of yield traps in the share market and understanding yield traps is an important step. Daniel Ortisi of Stock Doctor tells us how to avoid yield traps, with Peter Warren Automotive Holdings Ltd (ASX: PWR), Telstra Group Ltd (ASX: TLS), APA Group (ASX: APA), and Commonwealth Bank of Australia (ASX: CBA) as key examples.
Members of the Stock Doctor analyst team attended the Trajan Group Holdings (ASX:TRJ) inaugural shareholder day on Monday the 30th of October. This gave us an opportunity to further understand the business, meet management and visit its manufacturing facility in Ringwood, Melbourne.
Is Lynas Rare Earths Ltd (ASX: LYC) a still buy today after its licence extension in Malaysia? Daniel Ortisi from Stock Doctor tells us what changes this will bring to the ASX share market.
Rising bond yields, oil prices, and now heightened geopolitical tensions in the Middle East have seen equity markets pull back. The S&P/ASX 200 (INDEXASX: XJO) is effectively flat year-to-date, giving up gains of close to 8% seen in July.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
